There is no such thing as a positive antinuclear antibody profile that confirms the diagnosis of scleroderma. Generally speaking, a positive topoisomerase 1 (Scl-70) antibody test on the antinuclear antibody panel is associated with scleroderma, but the antibody result alone does not confirm the diagnosis of scleroderma. 1. Scleroderma is a connective tissue disease of unknown origin, characterized by the deposition and sclerosis of collagen fibers, resulting in limited or diffuse skin thickening and fibrosis, as well as structural abnormalities of internal organs (including the gastrointestinal tract, lungs, kidneys and heart). 2. Depending on the extent of the skin lesions and the involvement of internal organs, they are categorized as focal scleroderma and systemic scleroderma, which is also known as systemic sclerosis. 3. Antibodies to topoisomerase 1 (Scl-70) are the characteristic antibody of systemic sclerosis. 20% to 56% of patients with scleroderma may show positive antibodies to topoisomerase 1, but antibody positivity does not necessarily mean scleroderma. 4. The diagnosis of scleroderma is based on thickening, tightness and swelling of the skin of the fingers and proximal metacarpophalangeal (metatarsophalangeal) joints. Fibrosis at the base of both lungs and depressed scarring between the fingers are also diagnostic conditions. When scleroderma is suspected, one should visit the hospital in time to get a clear diagnosis and then give targeted treatment.